Venus Medtech (Hangzhou) Inc. said the multicenter, prospective, single-arm, open-label study enrolled 157 symptomatic patients with at least severe tricuspid regurgitation who were considered high risk for open-heart surgery. Of these, 148 received the Cardiovalve TR System. The mean age was 78; 71% were women, 99% had secondary tricuspid regurgitation and nearly 40% had torrential regurgitation. The study met its primary performance and safety endpoints, the company said. Prof. Georg Nickenig of the Heart Center at University Hospital Bonn presented the data on behalf of the investigators.
The primary performance endpoint—successful implantation with tricuspid regurgitation reduced to 2+ or less at 30 days—was met. Improvements in functional capacity and quality of life were maintained during follow-up: the mean six-minute walk test distance increased by 42 meters at one year, and the Kansas City Cardiomyopathy Questionnaire score rose by 20 points. At three years, 80% of patients were in New York Heart Association Class I or II, compared with 39.9% at baseline. Mean reductions in right-heart measurements at three years included 25% in inferior vena cava diameter, 22% in mid right ventricular end-diastolic diameter and 11% in basal right ventricular end-diastolic diameter.



Comments (0)
No comments yet. Be the first!